文献速递心胸血管麻醉

Vasculotide(血管生成素-1模拟物)减少大鼠体外循环中的肺血管渗漏并保留微循环灌注

Vasculotide, an angiopoietin-1 mimetic, reduces pulmonary vascular leakage and preserves microcirculatory perfusion during cardiopulmonary bypass in rats.
PubMed 文献 · Br J Anaesth · 2018-06-19

本研究在大鼠体外循环(CPB)模型中探讨靶向Tie2的血管生成素-1模拟物Vasculotide对血管渗漏和微循环灌注的影响。结果显示CPB导致微循环灌注受损及肾、肺Evans蓝渗漏增加,Vasculotide治疗保留了微循环灌注并减少肺(而非肾)的Evans蓝外渗。

要点

  • CPB后微循环灌注立即受损,Vasculotide治疗可保留灌注。
  • Vasculotide减少CPB后肺Evans蓝渗漏(P=0.04),但对肾无显著影响(P=0.38)。
  • Vasculotide不影响循环或组织中Ang-1、Ang-2、Tie2的表达。

核心结论

  • 在大鼠CPB模型中,血管生成素-1模拟物Vasculotide减少了肺血管渗漏并保留了微循环灌注。

研究设计与样本

  • 大鼠接受75分钟CPB,随机给予Vasculotide或磷酸盐缓冲液(对照),或行假手术。
  • 微循环灌注和渗漏分别通过活体显微镜(每组n=10)和Evans蓝染料外渗(每组n=13)评估。
  • 检测血浆、肾脏和肺中Angiopoietin-1、-2及Tie2的蛋白和基因表达。

主要发现

  • 与假手术组相比,未治疗CPB大鼠微循环灌注立即受损[5(4-8)vs 10(7-12)血管/记录,P=0.002],且在脱离CPB后持续存在。
  • CPB增加了循环Angiopoietin-1、-2和可溶性Tie2浓度,并降低了肾和肺中Tie2 mRNA表达。
  • CPB增加了肾[12(8-25)vs 7(1-12)μg/g,P=0.04]和肺[23(13-60)vs 6(4-16)μg/g,P=0.001]的Evans蓝渗漏。
  • Vasculotide治疗保留了CPB期间和之后的微循环灌注,并减少了肺Evans蓝外渗[18(6-28)μg/g vs 23(13-60)μg/g,P=0.04],但对肾无显著影响[10(3-23)vs 12(8-25)μg/g,P=0.38]。
  • Vasculotide未影响循环或mRNA表达的Angiopoietin-1、-2和Tie2浓度。

关键数值与推荐

  • 微循环灌注以每记录血管数表示,CPB未治疗组5(4-8)vs 假手术组10(7-12),P=0.002。
  • 肺Evans蓝渗漏:Vasculotide组18(6-28)μg/g vs CPB对照组23(13-60)μg/g,P=0.04。
  • 肾Evans蓝渗漏:Vasculotide组10(3-23)μg/g vs CPB对照组12(8-25)μg/g,P=0.38。

临床怎么用

  • Vasculotide可能作为CPB期间保护肺血管屏障和微循环灌注的潜在治疗策略,但需进一步临床研究验证。

局限性

  • 本研究为大鼠模型,结果不能直接推广至人类。
  • Vasculotide对肾脏血管渗漏无显著保护作用,器官特异性效应需进一步探讨。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiopulmonary bypass (CPB) during cardiac surgery impairs microcirculatory perfusion and is paralleled by vascular leakage. The endothelial angiopoietin/Tie2 system controls microvascular leakage. This study investigated whether targeting Tie2 with the angiopoietin-1 mimetic vasculotide reduces vascular leakage and preserves microcirculatory perfusion in a rat CPB model. METHODS: Rats were subjected to 75 min of CPB after treatment with vasculotide or phosphate buffered solution as control or underwent a sham procedure. Microcirculatory perfusion and leakage were assessed with intravital microscopy (n=10 per group) and Evans blue dye extravasation (n=13 per group), respectively. Angiopoietin-1, -2, and Tie2 protein and gene expression were determined in plasma, kidney, and lung. RESULTS: CPB immediately impaired microcirculatory perfusion [5 (4-8) vs 10 (7-12) vessels per recording, P=0.002] in untreated CPB rats compared with sham, which persisted after weaning from CPB. CPB increased circulating angiopoeietin-1, -2, and soluble Tie2 concentrations and reduced Tie2 messenger ribonucleic acid (mRNA) expression in kidney and lung. Moreover, CPB increased Evans blue dye leakage in kidney [12 (8-25) vs 7 (1-12) μg g-1, P=0.04] and lung [and 23 (13-60) vs 6 (4-16) μg g-1, P=0.001] compared with sham. Vasculotide treatment preserved microcirculatory perfusion during and after CPB. Moreover, vasculotide treatment reduced Evans blue dye extravasation in lung compared with CPB control [18 (6-28) μg g-1vs 23 (13-60) μg g-1, P=0.04], but not in kidney [10 (3-23) vs 12 (8-25) μg g-1, P=0.38]. Vasculotide did not affect circulating or mRNA expression of angiopoietin-1, -2, and Tie2 concentrations compared with untreated CPB controls. CONCLUSIONS: Treatment with the angiopoietin-1 mimetic vasculotide reduced pulmonary vascular leakage and preserved microcirculatory perfusion during CPB in a rat model.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Dekker NAM, van Meurs M, van Leeuwen ALI, et al. Vasculotide, an angiopoietin-1 mimetic, reduces pulmonary vascular leakage and preserves microcirculatory perfusion during cardiopulmonary bypass in rats. Br J Anaesth. 2018. PMID: 30336848. doi:10.1016/j.bja.2018.05.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。